Open Sidebar

EURO-PERISCOPE

The European Platform for Research Outcomes after PerIoperative Interventions in Surgery for Cancer Research Group (Euro-Periscope): The Onco-Anaesthesiology Research Group (RG)

Chair: Daniela Ionescu (Iuliu Hatieganu University of Medicine and Pharmacy, Cluj, Romania).

Vice-Chair: Oscar Cambronero Diaz (Hospital Universitari i Politècnic la Fe, Valencia, Spain).

Background

ESAIC endorsed The European Platform for Research Outcomes after Perioperative Interventions for Surgery for Cancer (Euro-Periscope) as a Research Group (RG) at the start of 2020. It emerged from EU-COST Action 15204 (2016-2020) of the same name.

Objectives

The objectives of ESAIC Euro-Periscope RG are:

1. To advocate for perioperative care of cancer patients, because complex cancer surgery for increasingly frail patients requires increasingly specialised care, meriting specific fellowship training and status as a recognised sub-specialty within anaesthesiology
2. To promote research and quality improvement initiatives in perioperative management of cancer patients, focused not only on improving long term oncologic outcomes, but also on short term outcomes (e.g. QoR-15, Days at Home at 30 days, reduced 30-day complications) that may also enhance longer term overall outcomes
3. To promote networking in research in anaesthesia and cancer between anaesthesiologists and other researchers in this field from different countries from EU and other countries around the world.

VAPOR- C Study design

VAPOR-C is an international multi-centre, prospective randomized 2×2 factorial design trial with the aim of including almost 5,900 patients in total and testing two hypotheses among patients undergoing surgery of curative intent with colorectal or non-small cell lung tumours.

Primary Objectives

1. Propofol TIVA increases Disease Free Survival compared with volatile sevoflurane anaesthesia;
2. Lidocaine perioperatively (bolus + continuous infusion until discharged from PACU) increases disease-free survival compared with patients not receiving any lidocaine.

Secondary Objectives

To compare propofol-TIVA versus sevoflurane in regards to:

• Days at Home for 30 days
• Overall Survival
• Post-operative complications
• Functional capacity
• Clinical frailty
• Acute postoperative pain (postoperative day 1-3)

Inclusion criteria

1. Male or female patients aged 18 years or older at screening
2. Has provided written informed consent for the trial
3. Patient with AJCC 8^th edition Stage I-III colorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytological diagnosis.

Exclusion criteria

1. Allergy to any of the anaesthetic drugs or techniques
2. Known existing metastasis

Patients will be followed up every 6 months post-surgery until the close-out date.

ENCORE

A prospective observational study sponsored by ESAIC.

Aiming for 10,000 Stage I-III colorectal cancer patients undergoing surgery of curative intent.

Primary Objectives:

1. To observe the effect of anaesthetic technique on:
2. Short term: time to start adjuvant chemotherapy in patients planned for RIOT
3. Long-term: Time to recurrence (TTR) at 2 years (± 1 month)

Secondary Objectives:

1. 30-day postoperative morbidity
2. Length of hospital stay and Days at home at 30 days (DAH-30)
3. Adverse events related to oncological treatment (chemotherapy, radiotherapy)
4. 1-year mortality

Inclusion Criteria:

1. Age > 18 years
2. ASA I-III
3. Scheduled for elective (planned) colorectal cancer surgery for stage I-III (open or laparoscopic)
4. Signed written informed consent when requested by the local Ethics committee

Exclusion Criteria:

1. Uncontrolled renal or liver disease, restrictive (limiting mobility) heart failure or ischemic heart disease (ASA IV-V)
2. Speech, language or cognitive difficulties precluding signing informed consent to participate
3. Stage IV colorectal cancer